X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
male (61) 61
index medicus (48) 48
chemotherapy (45) 45
oncology (41) 41
middle aged (38) 38
cancer (36) 36
adult (34) 34
aged (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
treatment outcome (26) 26
prognosis (25) 25
metastasis (23) 23
retrospective studies (23) 23
care and treatment (21) 21
prostate cancer (17) 17
urology & nephrology (17) 17
antineoplastic agents - therapeutic use (15) 15
disease-free survival (15) 15
female (15) 15
cisplatin (14) 14
cisplatin - administration & dosage (14) 14
aged, 80 and over (13) 13
survival (13) 13
therapy (13) 13
urology (13) 13
analysis (12) 12
bladder cancer (12) 12
combined modality therapy (12) 12
kaplan-meier estimate (12) 12
life sciences (12) 12
young adult (12) 12
docetaxel (11) 11
drug therapy (11) 11
hematology, oncology and palliative medicine (11) 11
neoplasm staging (11) 11
research (11) 11
survival analysis (11) 11
testicular cancer (11) 11
testicular neoplasms - pathology (11) 11
adolescent (10) 10
cancer therapies (10) 10
clinical trials (10) 10
follow-up studies (10) 10
metastases (10) 10
neoplasm metastasis (10) 10
neoplasms, germ cell and embryonal - drug therapy (10) 10
neoplasms, germ cell and embryonal - pathology (10) 10
taxoids - administration & dosage (10) 10
testicular neoplasms - drug therapy (10) 10
time factors (10) 10
urinary bladder neoplasms - drug therapy (10) 10
urinary bladder neoplasms - pathology (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
neoplasms, germ cell and embryonal - therapy (9) 9
patient outcomes (9) 9
prostatic neoplasms - drug therapy (9) 9
survival rate (9) 9
testicular neoplasms - surgery (9) 9
diagnosis (8) 8
gemcitabine (8) 8
germ cell tumors (8) 8
men (8) 8
tumors (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
disease progression (7) 7
health aspects (7) 7
high-dose chemotherapy (7) 7
lymphatic metastasis (7) 7
neoplasms, germ cell and embryonal - diagnosis (7) 7
patients (7) 7
prednisone (7) 7
prostatic neoplasms - mortality (7) 7
testicular neoplasms - therapy (7) 7
antineoplastic agents - adverse effects (6) 6
carboplatin (6) 6
clinical medicine (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - analogs & derivatives (6) 6
double-blind method (6) 6
drug administration schedule (6) 6
france (6) 6
lymph-node dissection (6) 6
open-label (6) 6
orchiectomy (6) 6
paclitaxel (6) 6
pain (6) 6
prospective studies (6) 6
prostatic neoplasms - pathology (6) 6
prostatic neoplasms, castration-resistant - drug therapy (6) 6
risk factors (6) 6
surgery (6) 6
testicular neoplasms - diagnosis (6) 6
trial (6) 6
urinary bladder neoplasms - mortality (6) 6
androgen antagonists - therapeutic use (5) 5
androgens (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - administration & dosage (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 787 - 794
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 417 - 425
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 760 - 768
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10122, pp. 748 - 757
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1442 - 1450
Summary Background Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST CYCLE | ETOPOSIDE | THERAPY | SOUTHWEST-ONCOLOGY-GROUP | CISPLATIN | ONCOLOGY | DENSE CHEMOTHERAPY | HIGH-DOSE CHEMOTHERAPY | COMPLETE-RESPONSE | CANCER | Testicular Neoplasms - mortality | Prognosis | Follow-Up Studies | Peritoneal Neoplasms - blood | Humans | Middle Aged | Male | Mediastinal Neoplasms - mortality | Neoplasms, Germ Cell and Embryonal - blood | Testicular Neoplasms - pathology | Cisplatin - administration & dosage | Young Adult | Mediastinal Neoplasms - drug therapy | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Oxaliplatin | Chorionic Gonadotropin - blood | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Paclitaxel - administration & dosage | Precision Medicine | alpha-Fetoproteins - metabolism | Peritoneal Neoplasms - pathology | Lenograstim | Mediastinal Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - mortality | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Peritoneal Neoplasms - mortality | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Ifosfamide - administration & dosage | International Agencies | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Adolescent | Aged | Neoplasm Staging | Testicular Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - pathology | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Tumors | Cancer | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 13, pp. 1187 - 1197
Journal Article
by Petrylak, Daniel and Petrylak, Daniel P and de Wit, Ronald and Chi, Kim Nguyen and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Yu-Li and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor and Percent, Ivor J and Lee, Yun-Gyoo and Lee, Hyo Jin and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia Z and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Sarid, David and Scagliotti, Giorgio Vittorio and Bracarda, Sergio and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and Hashine, Katsuyoshi and ... and RANGE Study Investigators and RANGE study investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BLADDER-CANCER | MEDICINE, GENERAL & INTERNAL | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | OPEN-LABEL | COMBINATION | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis
Journal Article